File Download
  • No File Attached
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B
  • Basic View
  • Metadata View
  • XML View
TitleHigh serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B
 
AuthorsWong, VWS2
Yu, J2
Cheng, ASL2
Wong, GLH2
Chan, HY2
Chu, ESH2
Ng, EKO2
Chan, FKL2
Sung, JJY2
Chan, HLY2 1
 
KeywordsCase-control studies
Cytokines
Fibrosis
Hepatitis B
Interleukin-6
Liver neoplasms
 
Issue Date2009
 
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
CitationInternational Journal Of Cancer, 2009, v. 124 n. 12, p. 2766-2770 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.24281
 
AbstractIncreased interleukin-6 (IL-6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL-6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case-control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty-seven patients developed HCC at a median follow-up of 62 months (interquartile range: 41-110). Serum IL-6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL-6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL-6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL-6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high-risk patients for HCC surveillance program. © 2009 UICC.
 
ISSN0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
DOIhttp://dx.doi.org/10.1002/ijc.24281
 
ISI Accession Number IDWOS:000265997500002
Funding AgencyGrant Number
Chinese University of Hong Kong2007.2.018
Research Fund of the Department of Medicine and Therapeutics
Funding Information:

Grant sponsors: The Chinese University of Hong Kong and the Research Fund of the Department of Medicine and Therapeutics, The Chinese University of Hong Kong; Grant number: 2007.2.018.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorWong, VWS
 
dc.contributor.authorYu, J
 
dc.contributor.authorCheng, ASL
 
dc.contributor.authorWong, GLH
 
dc.contributor.authorChan, HY
 
dc.contributor.authorChu, ESH
 
dc.contributor.authorNg, EKO
 
dc.contributor.authorChan, FKL
 
dc.contributor.authorSung, JJY
 
dc.contributor.authorChan, HLY
 
dc.date.accessioned2010-09-17T10:39:07Z
 
dc.date.available2010-09-17T10:39:07Z
 
dc.date.issued2009
 
dc.description.abstractIncreased interleukin-6 (IL-6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL-6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case-control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty-seven patients developed HCC at a median follow-up of 62 months (interquartile range: 41-110). Serum IL-6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL-6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL-6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL-6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high-risk patients for HCC surveillance program. © 2009 UICC.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationInternational Journal Of Cancer, 2009, v. 124 n. 12, p. 2766-2770 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.24281
 
dc.identifier.doihttp://dx.doi.org/10.1002/ijc.24281
 
dc.identifier.epage2770
 
dc.identifier.hkuros168711
 
dc.identifier.isiWOS:000265997500002
Funding AgencyGrant Number
Chinese University of Hong Kong2007.2.018
Research Fund of the Department of Medicine and Therapeutics
Funding Information:

Grant sponsors: The Chinese University of Hong Kong and the Research Fund of the Department of Medicine and Therapeutics, The Chinese University of Hong Kong; Grant number: 2007.2.018.

 
dc.identifier.issn0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
dc.identifier.issue12
 
dc.identifier.openurl
 
dc.identifier.pmid19267406
 
dc.identifier.scopuseid_2-s2.0-65649111667
 
dc.identifier.spage2766
 
dc.identifier.urihttp://hdl.handle.net/10722/92203
 
dc.identifier.volume124
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
dc.publisher.placeUnited States
 
dc.relation.ispartofInternational Journal of Cancer
 
dc.relation.referencesReferences in Scopus
 
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc.
 
dc.subject.meshCarcinoma, Hepatocellular - blood - virology
 
dc.subject.meshHepatitis B virus - isolation and purification
 
dc.subject.meshHepatitis B, Chronic - blood - virology
 
dc.subject.meshInterleukin-6 - blood
 
dc.subject.meshLiver Neoplasms - blood - virology
 
dc.subjectCase-control studies
 
dc.subjectCytokines
 
dc.subjectFibrosis
 
dc.subjectHepatitis B
 
dc.subjectInterleukin-6
 
dc.subjectLiver neoplasms
 
dc.titleHigh serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wong, VWS</contributor.author>
<contributor.author>Yu, J</contributor.author>
<contributor.author>Cheng, ASL</contributor.author>
<contributor.author>Wong, GLH</contributor.author>
<contributor.author>Chan, HY</contributor.author>
<contributor.author>Chu, ESH</contributor.author>
<contributor.author>Ng, EKO</contributor.author>
<contributor.author>Chan, FKL</contributor.author>
<contributor.author>Sung, JJY</contributor.author>
<contributor.author>Chan, HLY</contributor.author>
<date.accessioned>2010-09-17T10:39:07Z</date.accessioned>
<date.available>2010-09-17T10:39:07Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>International Journal Of Cancer, 2009, v. 124 n. 12, p. 2766-2770</identifier.citation>
<identifier.issn>0020-7136</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/92203</identifier.uri>
<description.abstract>Increased interleukin-6 (IL-6) production is implicated in the pathogenesis of hepatocellular carcinoma (HCC) in animal models. Although previous studies showed that HCC patients had higher serum IL-6 level at the time of diagnosis, it is unclear if the cytokine contributes to the development of HCC or is just a reaction to cancer. To address this question, we performed a nested case-control study. Consecutive chronic hepatitis B patients were recruited from 1997 to 2000 and followed till 2008. Profiling of 27 cytokines, chemokines and growth factors was performed at baseline, date of peak alanine aminotransferase (ALT) level and the last visit. Thirty-seven patients developed HCC at a median follow-up of 62 months (interquartile range: 41-110). Serum IL-6 was higher in patients with HCC than controls both during peak ALT and at the last visit (both p = 0.02). Patients with IL-6 above 7 pg/ml during peak ALT had increased risk of HCC or death (adjusted hazard ratio 3.0; 95% confidence interval 1.2, 7.8; p = 0.02). The sensitivity, specificity, positive and negative predictive values of this cutoff to predict future HCC development were 70%, 73%, 72% and 71%, respectively. Combination of IL-6 and AFP improved the sensitivity in diagnosing HCC or predicting future HCC development. In conclusion, high serum IL-6 level predates the development of HCC in chronic hepatitis B patients, and has moderate accuracy in predicting future cancer. This may assist clinicians in selecting high-risk patients for HCC surveillance program. &#169; 2009 UICC.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc.. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/journal/29331/home</publisher>
<relation.ispartof>International Journal of Cancer</relation.ispartof>
<rights>International Journal of Cancer. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject>Case-control studies</subject>
<subject>Cytokines</subject>
<subject>Fibrosis</subject>
<subject>Hepatitis B</subject>
<subject>Interleukin-6</subject>
<subject>Liver neoplasms</subject>
<subject.mesh>Carcinoma, Hepatocellular - blood - virology</subject.mesh>
<subject.mesh>Hepatitis B virus - isolation and purification</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - blood - virology</subject.mesh>
<subject.mesh>Interleukin-6 - blood</subject.mesh>
<subject.mesh>Liver Neoplasms - blood - virology</subject.mesh>
<title>High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0020-7136&amp;volume=124&amp;issue=12&amp;spage=2766&amp;epage=2770&amp;date=2009&amp;atitle=High+serum+interleukin-6+level+predicts+future+hepatocellular+carcinoma+development+in+patients+with+chronic+hepatitis+B</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/ijc.24281</identifier.doi>
<identifier.pmid>19267406</identifier.pmid>
<identifier.scopus>eid_2-s2.0-65649111667</identifier.scopus>
<identifier.hkuros>168711</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-65649111667&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>124</identifier.volume>
<identifier.issue>12</identifier.issue>
<identifier.spage>2766</identifier.spage>
<identifier.epage>2770</identifier.epage>
<identifier.isi>WOS:000265997500002</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. Prince of Wales Hospital Hong Kong
  2. Chinese University of Hong Kong